Pharmacogenomics—a New Frontier for Individualized Treatment of Parkinson’s Disease

BACKGROUND: Parkinson’s disease (PD) is the second most common neurodegenerative disease with a significant public health burden. It is characterized by the gradual degeneration of dopamine neurons in the central nervous system. Although symptomatic pharmacological management remains the primary the...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jia-Si, Chen, Ying, Shi, Dan-Dan, Zhang, Bao-Rong, Pu, Jia-Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2023
Materias:
Medicine, Neurology, Pharmacology, Neuroscience
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207905/
https://www.ncbi.nlm.nih.gov/pubmed/36582064
http://dx.doi.org/10.2174/1570159X21666221229154830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207905/
https://www.ncbi.nlm.nih.gov/pubmed/36582064
http://dx.doi.org/10.2174/1570159X21666221229154830

Ejemplares similares